Projekt

Metabotropic Glutamate Receptor 5 Imaging in Amyotrophic Lateral Sclerosis (ALS) Using Positron Emission Tomography (PET)

Laufend - Rekrutierung – laufend · 2022 bis 2025

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als Hauptzentrum
Bereiche
Status
Laufend - Rekrutierung – laufend
Start
2022
Ende
2025
Finanzierungsart
Andere
Studiendesign
Multizentrische Beobachtungsstudie
Schlagwörter (Tags)
ALS, neurodegenerative disease, PET, Biomarker
Projektpartner
ETH, Institut für pharmazeutische Wissenschaften, Zürich USZ, Klinik für Nuklearmedizin, Zürich
Kurzbeschreibung/Zielsetzung

Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder characterized by a progressive and selective loss of upper and lower motor neurons (MNs), causing weakness and ultimately death. Glutamate excitotoxicity has been suggested to play a major role in amyotrophic lateral sclerosis. Glutamate is acting upon ionotropic and metabotropic glutamate receptors. One of the metabotropic glutamate receptors, mGlurR5, is upregulated during progression of ALS in the SOD1 mouse model. By blocking mGluR5 in this mouse model, motor neuron degeneration slowed down and survival was slightly extended. Recently, we have been able to demonstrate upregulation of mGluR5 in post mortem brain tissue of ALS patients using the new mGluR5-specific radioligand [18F]PSS232.
Our project aims at studying mGluR5 upregulation during the course of ALS in humans, using the mGluR5-specific radioligand. If this project is successful, a biomarker would be available to visualize the progression of the disease and potentially could track the efficacy of new drugs.